Below is a recorded zoom presentation about Low-risk MDS & the REPAIR-MDS clinical trial. The discussion was hosted by the MDS Patient Support Group with presentations by the clinical trial investigators Dr Manoj Raghavan, Dr Stephen Jenkins, Dr Farhat Khanim and Professor Chris Bunce. The video gives valuable information about the trial and its potential benefits for patients with low-risk MDS.

The topics include:

• the current treatment options for Low-Risk MDS
• a description of the REPAIR-MDS clinical trial and the general clinical trial processes
• explanations of: eligibility for the trial, expectations, treatment periods, schedule of events, importance of completing the trial and where to find out about the progress of the trial.
• The presentation was followed by Q&As with a large group of MDS patients.

The meeting was held on 27th January 2023 and was chaired by Sophie Wintrich, CEO and Trustee of MDS UK Patient Support Group. For more on the specialist speakers, see their profiles below.

Dr Manoj Raghavan is Co-Chief Investigator on the REPAIR-MDS trial in low/ intermediate risk MDS. He is a consultant haematologist based at the Centre for Clinical Haematology.

Dr Stephen Jenkins is Co-Chief Investigator on the REPAIR-MDS trial and consultant haematologist at Russells Hall Hospital, Dudley.

Dr Farhat Khanim is Co-investigator on the REPAIR-MDS trial and is a translational cancer biologist at the School of Biosciences University of Birmingham.

Professor Chris Bunce is Professor of Translational Cancer Biology and Head of Research. He directs a translational research group dedicated to the development of novel therapies for leukaemias and lymphomas at the School of Biosciences University of Birmingham